Condition: Solid Malignancies · Sponsor: Carrick Therapeutics Limited
This modular, multi-part, multi-arm, Phase 1/2, FIH study allows the evaluation of the safety and tolerability of CT7439, dosed as a monotherapy and in combination with anticancer treatment in participants with solid malignancies.
This description comes directly from the study's public registry record.
Clinical Operations · +353 1 5996873 · hello@carricktherapeutics.com
Always discuss trial participation with your own doctor first.
| Research site 03 | Dallas, Texas, United States | Recruiting |
| Research site 01 | San Antonio, Texas, United States | Recruiting |
| Research site 02 | Fairfax, Virginia, United States | Recruiting |
| Research site 05 | Manchester, United Kingdom | Recruiting |
| Research site 04 | Oxford, United Kingdom | Recruiting |
| Research site 06 | Sutton, United Kingdom | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06600789